Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Metastatic Renal Cell Carcinoma

NCT03829111 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03829111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03829111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Metastatic Renal Cell Carcinoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Completed
Start date
May 14, 2019
Completion date
December 13, 2023
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma, clear cell renal cell carcinoma, metastatic renal cell carcinoma, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8, unresectable renal cell carcinoma